

DSM Pharmaceutical Products

45 Waterview Blvd
Parsippany, NJ 07054-1298

DSM Is Nominated for the CPhI Innovation Award

(Parsippany – September 24, 2007)

DSM Pharmaceutical Products, a leading provider of contract development and manufacturing services is pleased to announce today their nomination to receive the CPhI Innovation Award. DSM has been nominated for their work on the use of MonoPhos™ ligands in asymmetric hydrogenations. The CPhI Innovation Award has been established as the showcase for exceptional work in developing research and technology. The CPhI Innovation Awards are setting the standards for the pharmaceutical manufacturing industry.

The MonoPhos™ family of ligands has revolutionized the methodology that is used to prepare a wide range of chiral molecules in high yield and with excellent selectivity. Unlike more traditional ligands used for asymmetric hydrogenations, the DSM ligands can be made in fewer steps, thus increasing production time. The simple synthesis of the MonoPhos™ ligands and the ability to mix them for synergistic effects in a reaction provides diversity that is not available with the traditional families of ligands.

The DSM approach has allowed the whole procedure, from preparation of the ligand, catalyst preparation and hydrogenation to be performed by a robot in apparatus that runs 96 reactions at a time. This allows hundreds of reactions to be run in a week to find the optimal reaction conditions. This new methodology allows for a more efficient production time with decreased costs.

Ronald Gebhard, R&D Director, DSM Pharmaceutical Products comments, "The parallel approach to ligand synthesis and screening enables an increased time factor benefit to our customers. Instead of taking weeks to prepare a traditional bisphosphine ligand, our ligands can be made in a few hours. This also has advantages when we move to commercial product as preparation of the ligand has been simplified."

This methodology has been integrated from research, into commercial production and is currently being used at the DSM's large scale manufacturing facility located in Linz, Austria.

Johannes de Vries, DSM Principal Scientist Homogeneous Catalysis, comments, "The use of MonoPhos™ ligands is not only limited for large-scale asymmetric hydrogenations. In collaboration with the University of Groningen, DSM is investigating other exciting applications of catalysts including the formation of carbon-carbon bonds, an approach that could result in shorter synthesis of drug compounds."

About DSM Pharmaceutical Products

DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing services to the pharmaceutical and biopharmaceutical industries.

DSM Pharmaceutical Products provides contract manufacturing services including: advanced intermediates, active ingredients (API's), amino acids and derivatives, mammalian cell culture production (fed-batch and perfusion) of monoclonal antibodies, proteins, vaccines, finished dose manufacturing of solid dose, scheduled drugs, liquids, aseptic liquid and lyophilized products.

From clinical to commercial services, DSM focuses the right resources on providing the highest level of service and quality while applying innovative solutions to satisfy customers' unique manufacturing needs.

About DSM

DSM is active worldwide in [nutritional and pharma ingredients, performance materials and industrial chemicals](#). The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named [Vision 2010 – Building on Strengths](#), focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over €8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with [locations](#) in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com.

Forward-looking statements

This press release contains forward-looking statements. These statements are based on current expectations, estimates and projections of DSM management and information currently available to the company. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.

For more information:

DSM Pharmaceutical Products

Dr. Ronald Gebhard
Director Research & Development
+31 46 4761514
ronald.gebhard@dsm.com